Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
- On the first day, study participants will undergo 2 MRI examinations. A scan will be
done prior to administration of the contrast agent (Feraheme) and then a second scan
immediately after administration. On the second day, study participants will be asked
to return for a third MRI.
- All MRI scans will be done at Massachusetts General Hospital.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
To determine the sensitivity and specificity of high resolution magnetic resonance imaging with lymphotrophic superparamagnetic nanoparticles to identify small and otherwise undetectable lymph node metastases.
3 years
Yes
Ralph Weissleder, MD, PhD
Principal Investigator
Massachussetts General Hospital
United States: Institutional Review Board
08-085
NCT00920023
July 2008
October 2013
Name | Location |
---|---|
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |